- Home
- EFR vs MREO Comparison
EFR vs MREO Comparison
Compare EFR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFR
- MREO
- Stock Information
- Founded
- EFR 2003
- MREO 2015
- Country
- EFR United States
- MREO United Kingdom
- Employees
- EFR N/A
- MREO N/A
- Industry
- EFR Trusts Except Educational Religious and Charitable
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- EFR Finance
- MREO Health Care
- Exchange
- EFR Nasdaq
- MREO Nasdaq
- Market Cap
- EFR 342.8M
- MREO 281.6M
- IPO Year
- EFR N/A
- MREO N/A
- Fundamental
- Price
- EFR $11.58
- MREO $1.73
- Analyst Decision
- EFR
- MREO Strong Buy
- Analyst Count
- EFR 0
- MREO 5
- Target Price
- EFR N/A
- MREO $7.40
- AVG Volume (30 Days)
- EFR 88.6K
- MREO 910.9K
- Earning Date
- EFR 01-01-0001
- MREO 11-11-2025
- Dividend Yield
- EFR 9.43%
- MREO N/A
- EPS Growth
- EFR N/A
- MREO N/A
- EPS
- EFR 1.69
- MREO N/A
- Revenue
- EFR N/A
- MREO $500,000.00
- Revenue This Year
- EFR N/A
- MREO N/A
- Revenue Next Year
- EFR N/A
- MREO $55.50
- P/E Ratio
- EFR $7.74
- MREO N/A
- Revenue Growth
- EFR N/A
- MREO N/A
- 52 Week Low
- EFR $10.95
- MREO $1.47
- 52 Week High
- EFR $13.29
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- EFR 34.37
- MREO 45.94
- Support Level
- EFR $11.10
- MREO $1.68
- Resistance Level
- EFR $11.71
- MREO $1.88
- Average True Range (ATR)
- EFR 0.11
- MREO 0.08
- MACD
- EFR -0.00
- MREO 0.01
- Stochastic Oscillator
- EFR 72.73
- MREO 31.82
About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).